Monoclonal antibody therapeutics for inflammatory diseases
Strategic Profile
Allakos' primary product candidate is Antolimab (AK002), an investigational monoclonal antibody that selectively targets Siglec-8, a receptor found on mast cells and eosinophils, which play a key role in various allergic and inflammatory conditions. The company's R&D efforts are concentrated on conditions such as Eosinophilic Gastrointestinal Diseases (EGIDs), where Antolimab met all primary and secondary endpoints in a Phase 2 study, leading to the initiation of a Phase 3 study.
Cyborg Score Rationale
Allakos was acquired at a significant discount ($0.33/share) in May 2025, indicating shareholder value destruction and difficulty progressing clinical-stage antibody programs to commercialization. The company faced biotech sector headwinds and insufficient clinical momentum to maintain standalone operations.
Top Insights
(April 2025) Acquired by Concentra Biosciences for $0.33 per share in all-cash transaction after failing to maintain public company status
Focus on Siglec-targeted monoclonal antibodies for underserved mast cell and eosinophil-driven allergic and inflammatory diseases
Advanced late-stage clinical programs in Eosinophilic Gastrointestinal Diseases with Phase 3 initiation demonstrates scientific validation
Now operates as subsidiary with access to larger parent company resources to advance development programs forward
Named Competitors
Corvus Pharmaceuticals — Clinical-stage biopharmaceutical company developing immunomodulatory therapeutics